[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors",
    "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=5a71a4b47d8aefec2db583b63defe09799dc7badae05d37eb5ff04a2101eebbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735686022,
      "headline": "Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors",
      "id": 132228086,
      "image": "https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=5a71a4b47d8aefec2db583b63defe09799dc7badae05d37eb5ff04a2101eebbd"
    }
  },
  {
    "ts": null,
    "headline": "Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago are up 79%",
    "summary": "Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price drop...",
    "url": "https://finnhub.io/api/news?id=5f5e0bd3db8ccc21039bbea2bdcc77858ac2dcce68136aae64db88aacda8077a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735642834,
      "headline": "Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago are up 79%",
      "id": 132215226,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price drop...",
      "url": "https://finnhub.io/api/news?id=5f5e0bd3db8ccc21039bbea2bdcc77858ac2dcce68136aae64db88aacda8077a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested",
    "summary": "Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified pipeline. See my thoughts on VRTX.",
    "url": "https://finnhub.io/api/news?id=7756a79ae04b7af7be36a314afde90b18c95f235f326ab60e48b363f7e3fab96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735635767,
      "headline": "Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested",
      "id": 132214140,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291337814/image_1291337814.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified pipeline. See my thoughts on VRTX.",
      "url": "https://finnhub.io/api/news?id=7756a79ae04b7af7be36a314afde90b18c95f235f326ab60e48b363f7e3fab96"
    }
  }
]